It requires the binding of membrane type 1 MMPs (MT1-MMPs) with the tissue inhibitor of metalloproteinase type 2 (TIMP2) (Lehti et al. 1998; Nagase et al. 2006).
PT: Patellar tendon; PGs: proteoglycans; ECM: extracellular matrix; GAGs: glycosaminoglycans; Cox-2: cyclooxygenase 2; prostaglandinlandin E2; MMP-1: matrix metalloproteinase 1; MMPs: matrix metalloproteinases; RGB: hexadecimal values of Red, Green, Blue.
As is apparent by the information presented here and summarized in Table 1 and Fig. 1, MMPs have the potential to influence many biological processes during the pathogenesis of tissue fibrosis.
Based on the review of literature (as summarized in Table 1), MMPs and TIMPs cannot be applied for the routine diagnostic of TA yet and the clinical utility of these molecules remains to be established.
There are many other activators of PARs in addition to thrombin and trypsin (Table 1).> -wrap-foot> Source: [ 15, 29, 32, 37– 40] APC activated protein C, MT-SP1 membrane-type serine protease 1, MMPs matrix metalloproteinases Soon after the discovery of the thrombin receptor on normal human tissues, biologically functional receptor was also demonstrated in human cancer cells [ 14, 41, 42].
This subfamily includes, among others, collagenase 1 (MMP-1), and collagenase 3 (MMP-13).
To elucidate which MMP plays the primary role in cleaving MBP, we determined the efficiency of MMP-2, MMP-8, MMP-9, MMP-10, MMP-12, MT1-MMP, MT2-MMP, MT3-MMP, MT4-MMP, MT5-MMP and MT6-MMP in the cleavage of the MBP, BG21 and J37 isoforms in the in vitro cleavage reactions followed by mass-spectroscopy analysis of the cleavage fragments.
Among them, 7717 MMPs with the same outcomes consist of 7623 inactive MMPs and 94 active MMPs.
Obesity is usually associated with overload of proinflammatory cytokines including IL-6, TNF- α, and MCP-1, MMPs and fatty acid binding protein produced by visceral fat, macrophages, and adipocytes [ 1].
HGF would induce expression of ETS-1 target genes include the ETS-1, MMPs, urokinase-type plasminogen activator, growth factors and the growth factor receptor like c-Met or HER2 [ 25– 27].
These biomarkers are derived from different fields like melanocytic differentiation (e.g. tyrosinase; see Fig. 1), tumour angiogenesis (e.g. VEGF, bFGF, IL-8), cell adhesion and motility (e.g. ICAM-1, MMPs), cytokines and their receptors (e.g. IL-6, IL-10), antigen presentation (e.g. HLA molecules), tumour cell metabolism (e.g. TuM2-PK), apoptosis (e.g. Fas/CD95) and many others (see Table 1).
